Table 2.
Immediately precoronary angiography | Immediately postcoronary angiography | 3 months after coronary angiography | 6 months after coronary angiography | 12 months after coronary angiography | |
---|---|---|---|---|---|
Global EF (%) | 46 ± 10 | 47 ± 7a | 46 ± 9a | ||
The size of infarct area (%) | 29 ± 9 | 28 ± 9a | 26 ± 8a | ||
Infarct wall movement velocity (cm/s) | 1.86 ± 0.96 | 1.93 ± 0.76a | 1.99 ± 0.9a | ||
LVEDV (mL) | 141 ± 28 | 142 ± 31a | 140 ± 30a | ||
LVESV (mL) | 76 ± 17 | 75 ± 15a | 76 ± 16a | ||
SVI (mL/m) | 36 ± 10 | 35 ± 8a | 34 ± 9a | ||
CD34/45+ BM-CPCs | 200 ± 50 | 198 ± 53a | 212 ± 89a | 200 ± 75a | 205 ± 80a |
CD133/45+ BM-CPCs | 51 ± 38 | 51 ± 25a | 57 ± 28a | 64 ± 25a | 58 ± 19a |
BNP (pg/mL) | 169 ± 95 | 128 ± 97a | 138 ± 59a | 125 ± 70a | |
NYHA classification | 2.50 ± 0.9 | 2.30 ± 0.7a | 2.40 ± 0.7a | 2.29 ± 0.9a |
Values are mean ± SD.
There was no significant difference in baseline cardiac function, clinical function status parameters, as well as mobilization of BM-CPCs between both groups at baseline.
P = not significant.
BM-CPCs, bone marrow-derived circulating progenitor cells; NYHA, New York Heart Association; BNP, B-type natriuretic peptide; EF, ejection fraction; LVEDV, end-diastolic volume; LVESV, end-systolic volume; SVI, stroke volume index.